A Double-Blind, Randomized, Placebo-Controlled, Single-Centre Phase I Pharmacodynamic Cross-Over Study to Assess the Effect of a Single Dose of AZD2066 Oral Solution in Comparison to Placebo on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in Healthy Subjects.
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2012
At a glance
- Drugs AZD 2066 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Pharmacodynamics
- 06 Dec 2010 Trial phase changed from I to I/II as reported by ClinicalTrials.gov.
- 18 Nov 2009 Actual number of patients (40) added as reported by ClinicalTrials.gov.
- 18 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History